Litcius/Paper detail

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

Bjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten, Odd Terje Brustugun, Kjersti Hornslien, Tesfaye Madebo, Seppo W. Langer, Tine Schytte, Jan Nyman, Signe Risum, Georgios Tsakonas, Jens Engleson, Tarje Onsøien Halvorsen

2021The Lancet Oncology138 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOpen labelStage (stratigraphy)Radiation therapyOncologyLung cancerRandomized controlled trialInternal medicineRadiologyBiologyPaleontologyLung Cancer Research StudiesLung Cancer Treatments and MutationsNeuroendocrine Tumor Research Advances
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial | Litcius